Most Read Articles
Roshini Claire Anthony, 4 days ago

The combined use of piperacillin and tazobactam does not appear to be a suitable alternative to meropenem for patients with bloodstream infections caused by ceftriaxone-resistant Escherichia coli (E. coli) or Klebsiella pneumoniae (K. pneumoniae), according to results of the MERINO* trial.

Tristan Manalac, 19 May 2018
Taking oral antibiotics appears to increase the risk of nephrolithiasis, according to a recent study. Moreover, the risk seems to be compounded for individuals with recent antibiotic exposure and those who were exposed at a younger age.
2 days ago
Patients with inflammatory bowel disease are at increased risk of developing acute myocardial infarction (AMI) or heart failure, although the prevalence of traditional risk factors for such cardiovascular disorders appears to be low, as reported in a recent study.
3 days ago
Early renin-angiotensin-aldosterone system (RAAS) blockade with renin-angiotensin system inhibitors (RASI) leads to better short- and long-term renal outcomes in systemic lupus erythematosus (SLE) patients with antiphospholipid-associated nephropathy (aPLN), according to a study, adding that this renal protective effect is independent of RASI’s antihypertensive and antiproteinuric effects.

Intravitreous anti-VEGF drugs slightly reduce intraocular pressure

03 May 2018

Intravitreous injections of antivascular endothelial growth factor (anti-VEGF) drugs result in small but statistically significant decrease in intraocular pressure (IOP) over time, a recent database study has shown. Overall, 2.6 percent of eyes have a sustained clinically significant IOP rise compared with 1.5 percent in the fellow untreated eyes, but such an increase is not observed with aflibercept.

Participants were unique patients (n=23,776) who received only a single type of anti-VEGF medication (bevacizumab, aflibercept or ranibizumab) by injection in the right eye in the American Academy of Ophthalmology Intelligent Research in Sight Registry. Included in the subgroups were patients with age-related macular degeneration only and those who had not received anti-VEGF injection for at least 1 year prior to the study.

The authors examined patients with at least 12, 18 and 25 injections for each of the three medications. They used fellow untreated eyes for comparison for all groups. The primary endpoints were the mean change in IOP from baseline at a minimum of 1 year of follow-up and the proportion of eyes with a clinically significant IOP increase, defined as sustained rise of at least 6 mm Hg to an IOP of >21 mm Hg.

IOP decreased from baseline (mean, 0.9 mm Hg in treated eyes vs 0.2 mm Hg in fellow untreated eyes) in all patients in all groups receiving all drugs, showing a statistically significant difference. Bevacizumab was associated with slightly less lowering of IOP than aflibercept and ranibizumab in most subgroups, based on a generalized linear model accounting for confounders.

IOP significantly increased in 2.6 percent of eyes receiving injections compared with 1.5 percent in the associated untreated fellow eyes. The rate by which clinically significant IOP increases occurred was 1.9 percent for aflibercept, 2.8 percent for ranibizumab and 2.8 percent for bevacizumab, which was significantly higher for bevacizumab and ranibizumab, but not aflibercept, than fellow untreated eyes.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 4 days ago

The combined use of piperacillin and tazobactam does not appear to be a suitable alternative to meropenem for patients with bloodstream infections caused by ceftriaxone-resistant Escherichia coli (E. coli) or Klebsiella pneumoniae (K. pneumoniae), according to results of the MERINO* trial.

Tristan Manalac, 19 May 2018
Taking oral antibiotics appears to increase the risk of nephrolithiasis, according to a recent study. Moreover, the risk seems to be compounded for individuals with recent antibiotic exposure and those who were exposed at a younger age.
2 days ago
Patients with inflammatory bowel disease are at increased risk of developing acute myocardial infarction (AMI) or heart failure, although the prevalence of traditional risk factors for such cardiovascular disorders appears to be low, as reported in a recent study.
3 days ago
Early renin-angiotensin-aldosterone system (RAAS) blockade with renin-angiotensin system inhibitors (RASI) leads to better short- and long-term renal outcomes in systemic lupus erythematosus (SLE) patients with antiphospholipid-associated nephropathy (aPLN), according to a study, adding that this renal protective effect is independent of RASI’s antihypertensive and antiproteinuric effects.